My 8 followers on Weibo (Chinese equivalent of Twitter)

Really love this one!

Have signed with an Oxford UK publishing house a contract for 3 fictions, which should all be out before April 2017.

Doomsdare, a medical thriller (action taking place in Beijing)
Jesus CRISPR Superstar, a sci-fi, written with Isabelle Provost
French version of the sci-fi: La Passion Du CRISPR.

Then, from April 2017 on, will spend one year in Asia, emphasis on China. My very recent stays in Beijing? A shock, an ongoing one, one foot in fairy tale (thank you Cixin Liu) one foot in abyss (hashtag airpocalypse). Have seen a few things about the development of mHealth in China and want to explore... Thank you Jean-Michel Billaut (French blogger) for the tutorial sessions that should help me find ways to monetize those stays in Asia...

My (modest) mHealth Silk Road (LOL) project: Will explore startup incubators in Malaysia (Cyberjaya), North of Thailand and various parts of China from April to (at least) December 2017...

Have a passion for Chinese language and civilization anyway...

Of course, will attend mHealth congresses in China wearing Regina Holliday's jacket -- the one she painted for me... Chinese people usually love this jacket (from what I saw on a couple of opportunities in Beijing and Shanghai)...

8 followers on Weibo already, including Veritas Genetics (Shanghai), hopefully soon 12...

Biotech Books

#biotech @jdudley @konradjk @vsbuffalo @missionmassimo @leahkam @SystemsSally @krening @OReillyMedia @ninatandon TY. pic.twitter.com/Aup1AYoWwB

— CATHERINE COSTE (@cathcoste) August 28, 2015

First, the Human Genome Project with @eric_lander. Then, the Human Diagnosome Project with @missionmassimo @leahkam. pic.twitter.com/6q9uiRVzKH

— CATHERINE COSTE (@cathcoste) September 9, 2015

Solving Biology's Mysteries with Plants

"A life science recruiter's blog on placing R&D professionals"

.@Clarksearch "Any consideration 4 opportunity cost of letting a position sit empty while lots of time spent on finding perfect candidate?"
— CATHERINE COSTE (@cathcoste) August 7, 2014

What are life science job candidates supposed 2 do 2 navigate "algorithm-driven minefield?" http://t.co/rkv85sbW29 @Xconomy via @Clarksearch
— CATHERINE COSTE (@cathcoste) August 7, 2014

"There's no... law that says jobs eliminated by new tech will inevitably be replaced by new jobs in new markets… http://t.co/Z8CRwt9HoS
— Jason Pontin (@jason_pontin) August 6, 2014

"Bezos family donates $20M to Hutchinson Center (Seattle) to develop immunotherapy for solid tumors"

Bezos family donates $20M to @HutchinsonCtr to develop #immunotherapy for solid tumors -> http://t.co/kgfW6AjqcD pic.twitter.com/1iBYfKJzTn
— Andy Biotech (@AndyBiotech) April 7, 2014

"New eBook series offers practical advice for healthcare entrepreneurs from their peers "

New eBook series offers practical advice for healthcare entrepreneurs from their peers http://t.co/Ob0DegXDJd
— MedCity News (@medcitynews) April 8, 2014

" Genentech signs five-year collaboration with Patients Like Me for patient data"

We are excited to enter patient-centric research collaboration with @PatientsLikeMe http://t.co/FICWMRF4E0
— Genentech (@genentech) April 7, 2014

Wonder how pats will feel? RT @matthewherper: Genentech signs five-year collaboration with @patientslikeme for patient data. Interesting.
— Sally Church (@MaverickNY) April 7, 2014

"Big Data, Genetics and Translation"

I’ll be following @ewanbirney et al’s foray into drug target validation with great interest: http://t.co/XMpDPCElLC
— Daniel MacArthur (@dgmacarthur) March 27, 2014

http://genomeinformatician.blogspot.co.uk/2014/03/big-data-genetics-and-translation.html

"Drugs act on these targets. Drugs are often small molecules and sometimes proteins, like antibodies, that will change the activity of a biological target. A drug has to be able to enter the body, do what it was designed to do and not mess around doing other things. Pharmaceutical companies are really good at making these.

Clinical trials involve giving a new (or repurposed) drug to a group of consenting people. They are jaw-droppingly expensive. Unfortunately, the vast majority (90%) of drugs ultimately fail to make it through clinical trials. A large proportion of those fail because the information on which they were based, from right at the start – the target protein– was not quite right.

What’s the problem? In short, it is that a billion-dollar phase III clinical trial is a very expensive way to discover that your drug wasn't changing the right target."

"Which of these clusters do you think has the brightest future ahead in biopharma?"

http://genengnews.com/insight-and-intelligence/top-8-biopharma-clusters-in-asia/77900082

"Top 8 Biopharma Clusters in Asia"

• #8. Malaysia

  "Next year marks 10 years since the country established its National Biotechnology Policy aimed at growing the industry into a 5% contributor to GDP by 2020. With six years to go, Malaysia has some accomplishments—including its number of companies (seventh with 200 as of 2012), thanks in part to the BioNexus incentives program. A Malaysian billionaire, Genting Group Chairman Tan Sri Lim Kok Thay, is lead investor in J. Craig Venter’s Human Longevity, which vows to assemble the world’s largest human gene sequencing operation. And on Wednesday, Indonesian-based Kimia Farma said it will expand its Malaysian presence beyond a single dispensary in Sepang: 'The number will increase. Our sales in Malaysia have continued to increase,' corporate secretary Djoko Rusdianto told Antara News. Malaysia also placed eighth in patents (1,190) and R&D spending ($4.953 billion in 2011)."

• #7. Singapore

  "The dazzling Biopolis that anchors Singapore’s biopharma industry reflects how far the multi-ethnic city-state has come in building one of Asia’s fastest-growing industry clusters. Singapore hosts many of the largest industry giants including, Bayer, GlaxoSmithKline, Novartis, and Roche, which account for many of its biopharma jobs (37,735 in 2012). The country is sixth in venture capital ($17.7 million to three companies), and sixth in patents (3,068), but lower in number of companies (eighth at 95 as of 2012), and R&D (seventh at $6.987 billion, of which more than $1.5 billion is for biomedical research)—though considerable research activity occurs at 30 public-sector institutes under the Agency for Science, Technology and Research (known as A*STAR) and the Ministry of Health."

• #6. Australia

  "Despite embracing biopharma later than many Asian countries, Australia is actually second in the number of biotech and pharma patents (10,599), and fourth in number of companies (527 in 2011). The country saw investors flock to biopharma following the collapse of gold prices and an imploding mining sector, boosting both giants like ASX and new launches: 'How biotech finally boomed,' the Sydney Morning Herald headlined a feature on the industry in January. Australia ranked fifth in venture capital awards ($26.1 million to five companies) and sixth in IPOs ($6.8 million to Algae Tec in 2011). The land Down Under is also sixth in R&D spending (about $20.5 billion in 2010) but lags in number of jobs (13,000 as of last year)."

• #5. Taiwan

  "Officials have set their sights on growing biotech for some two decades, and since 2007 have passed three laws designed to improve the business climate, joining with private funds to raise more than $2 billion for startups. One priority has been government R&D funding, where Taiwan ranked fourth by spending about $27.5 billion. That spend has helped build jobs (19,332 in 2011) and homegrown businesses, where Taiwan ranks fourth in IPOs ($25.1 million to a single company, Taiwan Liposome in 2012) and sixth in number of companies (400 in 2011). The country ranked seventh in both patents (2,281) and 2013–14 venture capital, thanks to the $17 million won by Senhua Biosciences in December."

• #4. South Korea

  "Taking office last year, President Park Geun-hye excited biopharma industry leaders with her vision of a 'second miracle on the Han River.' The first was the transformation of the country a generation ago into an economic powerhouse by tying manufacturing with growth in several tech sectors—including biopharma, where South Korea shines in number of existing companies (second at 857 in 2010) and R&D spending (third at $65.394 billion in 2012). Earlier this month, Sanofi Pasteur said it will join homegrown SK Chemical to build a pneumococcal conjugate vaccine plant in Angdong. Domestic public company growth has stayed steady; South Korea finished fourth in patents (8,739) and fifth in IPOs ($17.5 million raised by a single company, Seegene) but startups lag, judging from a dearth of 2013–14 venture capital awards."

• #3. India

  "FDA Commissioner Margaret A. Hamburg, M.D., tried to balance criticism of some Indian drug manufacturers with praise for the country’s progress in building one of Asia’s biggest biopharma clusters with some 50,000 jobs (as of last year) during her recent trip to the subcontinent. Yet these days, even some industry professionals are critical; Krishna Ella, CMD of Bharat Biotech, complained: 'Students who graduate do not even know how to handle lab equipment sometimes.' India’s strengths are in company growth, ranking second in VC activity (more than $66 million to four companies) and fourth in IPOs (thanks to Claris Lifesciences raising $80 million in 2010). However, the country is fifth in both number of companies (about 500 as of last year) and at least fifth in R&D spending (figures range from $24.3 billion in 2007 to an estimated $40 billion in 2012), as well as fifth in patents (4,793)."

• #2. Japan

  "The Land of the Rising Sun may soon be eclipsed in biopharma by China, whose great leap forward over a generation contrasts with Japan’s economic stagnation. Prime Minister Shinzo Abe vows to grow a biotech industry alongside the legacy cluster of pharma giants, in part by speeding up decisions on new drugs and stepping up R&D spending; the nation will soon consolidate three agencies into a single research funding source akin to the U.S. NIH. Japan trails China in overall R&D funding (second at $151.8 billion in 2012); biomed R&D numbers vary wildly. There’s no question Japan’s on top in patents (39,797) and recent IPOs (nine companies raising $2.636 billion)—though the IPO figure was skewed by Otsuka Holdings’ $2.4 billion offering in 2010—while Japan finished third in companies (538 in 2011) and fourth in venture capital ($47.1 million to four companies)."

• #1. China

  "China didn’t grant patents until 1984, and didn’t issue patents for biopharma inventions until eight years later. That explains why the world’s most populous nation, which is at or near the top in many of GEN’s cluster criteria, places only third in biotech and pharma patents with 9,302. In the decades that have followed, China has caught up impressively in biopharma, leading Asia in R&D spending ($160 billion biomedical of a $243.4 billion recorded by OECD), companies (7,500 as of last year), jobs (more than 250,000 as of last year), and venture capital ($73.9 million to five companies), while coming in second to Japan in IPOs (just under $2.1 billion raised by an Asian-leading 14 companies). Years of massive government spending on research explains why, as does a domestic pharma-and-herbal medicine sector growing with global biopharma giants, many drawn by lower-than-Western labor costs."

 SOURCE: GEN -- Genetic Engineering & Biotech News

Meet e-patient Steve Jobs!

Meet e-patient Steve Jobs! http://t.co/brdZuagzbq #PMWC14 #genomics #meded #pm101 #personalized #medicine #indivmed #mHealth #Apple #biotech
— CATHERINE COSTE (@cathcoste) January 31, 2014

How Genetic Data Sharing Will Revolutionize Healthcare http://t.co/JNhExQ6Nkl #genomics #medicalfuture
— Berci Meskó, MD, PhD (@Berci) February 3, 2014

We need many more cancer genomes sequenced: http://t.co/FipTVKCt1J via @rahman_nazneen
— Daniel MacArthur (@dgmacarthur) February 7, 2014

Biologie de synthèse : vers une industrialisation du vivant ?

Débouchés intéressants pour les étudiants de l'école "42 Born To Code" à Paris...

Bio de synthèse : une industrialisation du vivant? http://t.co/RtXLiJGGra Débouchés intéressants pour étudiants 42 born to code @42Fabienne
— CATHERINE COSTE (@cathcoste) February 25, 2014

McCarthy completes JCVenterInst landmark netzero energy lab in La Jolla

McCarthy completes @JCVenterInst landmark #netzero energy lab in La Jolla. http://t.co/KzhdOa5RZD @ZGFArchitects #truebuilder
— McCarthy Building Co (@McCarthyBuild) February 21, 2014

A new micro-robotic technique for 3D-printing tissues

A new micro-robotic technique for 3D-printing tissues: A new magnetic micro-robotic technique for assembling c... http://t.co/jpiAUybUfZ
— KurzweilAINews (@KurzweilAINews) February 21, 2014

Welcome to the era of lab engineered body parts!

Human lung made in lab for first time http://t.co/KUb5CZwiW7

— CATHERINE COSTE (@cathcoste) February 18, 2014

"Engineering cells to repair the damage done by heart attacks."

"This micrograph, a winner in the Federation of American Societies for Experimental Biology’s 2013 BioArt Competition, shows cells that have been specially engineered to repair the damage done by heart attacks—which strike more than 700,000 Americans every year."

Great pic for Valentine's day http://t.co/QwleEycewG by @NIHDirector pic.twitter.com/EAIO2KZOEt
— Eric Topol (@EricTopol) February 14, 2014

"Working with rat heart muscle cells grown in a lab dish, NIH-supported bioengineers at Harvard Medical School used transplant techniques to boost the number of tiny powerhouses, called mitochondria, within the cells. If you look closely at the image above, you’ll see the heart muscle cells are tagged in green, their nuclei in blue, and their mitochondria in red.
Why on earth would a heart need extra mitochondria? At least in rat experiments, it turns out that hearts that receive additional mitochondria after a heart attack are more effective at repairing tissue damage and regaining function. The extra mitochondria make this possible by boosting energy generation, which in turn ramps up production of proteins vital for forming blood vessels, spurring cell migration to damaged tissue, and preventing cell death.
This approach holds considerable appeal because mitochondria are relatively easy to harvest from liver cells, do not trigger immune reactions when transplanted into heart cells, and could be combined with drugs or other therapies. What’s not to love about that?" (Source)

How Social Media and Big Data are Changing the Landscape of Surveillance and Research

How Social Media and Big Data are Changing the Landscape of Surveillance and Research http://t.co/5mrMDJsNbo
— CATHERINE COSTE (@cathcoste) February 14, 2014

"NASA tissue regeneration tech finds a home in medical devices for pain, 3D research models."

http://medcitynews.com/2014/02/nasa-tech-finds-new-home-noninvasive-medical-devices-3d-tissue-models-research/

Proudly Following Futuristech Info

Tweets by @FuturistechInfo

Novel method produces molecules designed from RNA sequence to create new drugs

Novel method produces molecules designed from RNA sequence to create new drugs http://t.co/BlU3I9ow1o pic.twitter.com/sc2iMeyIYu
— FUTURISTECH INFO (@FuturistechInfo) February 9, 2014

SAC trader's conviction closes the book on biotech's biggest insider scandal

SAC trader's conviction closes the book on biotech's biggest insider scandal http://t.co/oXyNeHY857
— Biotech Guide (@BiotechGuide) February 7, 2014